William Grossman, M.D., Ph.D., Named to BryoLogyx Board of Directors

“Dr. Grossman’s appointment occurs as we put in place the foundation for clinical development of our bryostatin-1 lead compound,” said Thomas Loarie, Co-Founder and CEO of BryoLogyx. “Dr. Grossman brings an extraordinary record of clinical accomplishment and cancer drug development and research leadership. We look forward to his guidance as we advance bryostatin-1 as a promising complement to cancer immunotherapies.”

Dr. Grossman joins BryoLogyx following his recent appointment as Chief Medical Officer at Arcus Biosciences. Prior to this appointment, Dr. Grossman served as the Chief Medical Officer at Bellicum Pharmaceuticals, a cellular-based therapy company. Dr. Grossman has held several other global oncology leadership positions including Group Development Team Lead for cancer immunotherapy combinations in solid tumors and late-stage GI at Genentech/Roche, the US and Global Medical Affairs Head of Oncology at AbbVie, as well as positions at Baxter Healthcare Corporation, Merck & Co., and Biothera Inc.

Dr. Grossman’s career in the pharmaceutical industry followed his tenure in clinical and academic medicine, specializing in cancer treatment and immunology. Previously, he had served as Associate Professor at Children’s Hospital of Wisconsin and the Medical College of Wisconsin in the Hematology/Oncology & Blood and Marrow Transplant Program, where he performed research in human immunology and was the Founder and Medical Director of the Clinical Immunodiagnostic and Research Laboratory and Immunodeficiency Program. Dr. Grossman earned his M.D. and Ph.D. (Immunology) degrees from the Washington University School of Medicine.

“It is a privilege to join the world class management and scientific teams at BryoLogyx. The company is poised to advance bryostatin at a time when the industry can be optimistic about bringing forward numerous therapeutics for manipulating the immune system to fight cancer,” said Dr. Grossman. “BryoLogyx has a vision to substantially benefit the survival of cancer patients, building on bryostatin research at the National Cancer Institute. I look forward to helping bring that vision to medical and commercial success.”

About BryoLogyx

BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies and anti-HIV agents. The company’s initial focus is on cancer, where it is capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development and use. BryoLogyx has exclusive rights from Stanford University to the method’s use in the areas of cancer and HIV. Bryostatin-1 is expected to enter Phase 1b clinical trials in 2020 to study its potential role in enhancing immuno-oncology drugs in the treatment of hematologic (blood) cancers. Learn more at www.bryologyx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005067/en/